The company is the subject of a securities class action lawsuit alleging violations of federal securities laws through false and misleading statements about its drug candidate, resulting in investor damages.
The company faces a class action lawsuit alleging false and misleading statements about its drug candidate ERAS-0015, patent infringement claims from a competitor, and experienced a 48% stock price decline following disclosure of these issues.
Company is accused of securities fraud involving misleading statements about drug safety, competitive advantages, and IP protections. Stock declined significantly following disclosure of patent infringement allegations and adverse clinical data including a patient death, resulting in $2.8 billion market cap loss.
Company made materially misleading statements about ERAS-0015 drug candidate, failed to disclose patent infringement risks from competitor Revolution Medicines, and reported a patient death from pneumonitis. Share price experienced substantial decline following April 2026 disclosures.
Company is subject to securities fraud investigation for allegedly misleading investors about drug safety, competitive advantages, and IP protections. Patent infringement allegations and adverse clinical data (patient death) led to significant stock decline and $2.8 billion market cap loss.
Company accused of making materially false statements regarding preclinical data based on improper comparisons, creating patent and trade secret violation risks.
Erasca faces allegations of securities fraud involving false statements about its lead drug candidate ERAS-0015, patent infringement claims from a competitor, and adverse clinical trial data resulting in significant stock price declines (11% and 48% on separate dates). These factors indicate serious legal and commercial challenges.
Company is accused of making false and misleading statements about its lead drug candidate ERAS-0015, including improper comparisons to competitors and undisclosed patent/trade secret disputes. Securities lawsuit alleges violations of federal securities laws resulting in investor damages.
The company faces a securities fraud class action lawsuit alleging failure to disclose patent and trade secret risks. A competitor claims patent infringement and trade secret misappropriation related to a key drug candidate. The stock experienced a notable decline of approximately 10.9% following the disclosure of these allegations.
The company is the subject of a securities class action lawsuit alleging violations of federal securities laws through false and misleading statements about its lead drug candidate, including improper comparisons and undisclosed patent/trade secret disputes that caused investor damages.
Company faces securities fraud allegations for making false statements about drug candidate ERAS-0015, including improper preclinical comparisons and failure to disclose patent infringement risks. Stock declined 59% following disclosure of patent assertion letter and adverse clinical data showing patient death.
The company is the subject of a securities class action lawsuit alleging violations of federal securities laws through false and misleading statements about its lead drug candidate, resulting in investor damages.
The company faces a class action lawsuit alleging false and misleading statements regarding its drug candidate ERAS-0015. A patent infringement claim from a competitor resulted in a 48% stock price decline, indicating serious legal and commercial risks to the company's credibility and financial performance.
The company is accused of making false and misleading statements about its drug candidate ERAS-0015, including improper data comparisons and patent infringement risks. These allegations resulted in investor losses and triggered a securities fraud class action lawsuit.
The company is the subject of a securities class action lawsuit alleging violations of federal securities laws through false and misleading statements about its lead drug candidate, improper competitive comparisons, and undisclosed patent/trade secret disputes. This represents significant legal and reputational risk to investors.
The company is the subject of a securities class action lawsuit alleging false and misleading statements about its lead drug candidate, improper competitive comparisons, and undisclosed patent/trade secret disputes, resulting in investor damages.
Company faces securities fraud allegations involving senior executives certifying false statements about clinical trial data. Stock declined 53.9% following corrective disclosures of patent infringement and patient death in trials. The company raised $258.8 million while allegedly concealing material information from investors.
The company successfully upsized its public offering and secured $550 million in gross proceeds at $17.50 per share, demonstrating investor confidence. The capital raise provides substantial funding for R&D of its oncology pipeline, which is positive for a clinical-stage company's ability to advance its drug candidates and achieve its mission in precision oncology.
Company faces securities fraud class action lawsuit alleging false statements about drug candidate efficacy, patent infringement claims from competitor, adverse clinical trial results including patient death, and significant stock price decline of approximately 59%.
The company is accused of making false and misleading statements about its lead drug candidate ERAS-0015, including improper comparisons to competitors and undisclosed patent/trade secret disputes. A securities class action lawsuit has been filed against the company and its executives, indicating potential investor losses.
Company faces federal securities class action lawsuit alleging false and misleading statements about drug candidate ERAS-0015. Disclosed patent infringement allegations, improper data comparisons, and a patient death in clinical trials, resulting in a 54% stock price decline over two trading days from $21.49 to $9.90 per share.
The company faces a class action lawsuit alleging material non-disclosure of patent and trade secret risks. A competitor's cease-and-desist letter regarding alleged infringement and improper data comparisons triggered a significant stock price decline of approximately 10.9%, indicating serious legal and reputational damage.
The company is the subject of a securities class action lawsuit alleging violations of federal securities laws through false and misleading statements about its lead drug candidate, improper competitive comparisons, and undisclosed patent/trade secret disputes. These allegations resulted in investor damages when the truth entered the market.
Company is defendant in class action lawsuit alleging materially false/misleading statements and failure to disclose material facts regarding ERAS-0015 during specified period.
Stock declined 48% ($9.25) following disclosure of patient death associated with ERAS-0015 and patent infringement allegations from Revolution Medicines. Company faces securities class action lawsuit for allegedly misleading investors about drug safety and IP protection. Over $2.8 billion in market capitalization was wiped out.
Company faces securities class action lawsuit due to alleged investor fraud involving misleading claims about ERAS-0015's efficacy and IP protection, combined with undisclosed patient death and patent infringement accusations from competitor Revolution Medicines, resulting in 48% stock decline and $2.8 billion market cap loss.
Company faces securities fraud allegations for making false/misleading statements about drug candidate ERAS-0015, including improper data comparisons and failure to disclose patent infringement risks. Stock declined 59% cumulatively following disclosure of patent assertion letter and adverse Phase I clinical data including a patient death.
Alleged improper preclinical data comparisons and patent/trade secret violation risks, with false positive statements about business operations and prospects.
The company is the subject of a securities fraud class action lawsuit alleging false and misleading statements about drug candidate ERAS-0015, improper data comparisons, and potential patent/trade secret violations. This represents significant legal and reputational risk to investors.
The company is the subject of a securities class action lawsuit alleging violations of federal securities laws through false and misleading statements about its lead drug candidate, improper competitive comparisons, and undisclosed patent/trade secret disputes. These allegations indicate serious corporate misconduct and regulatory violations.
Company faces shareholder litigation investigation for allegedly making false and misleading statements about its drug candidate without reasonable basis. Patent infringement and trade secret misappropriation allegations from a competitor resulted in a 10.9% stock price decline.
Company faces securities fraud allegations, patent infringement claims from competitor, patient death in clinical trial, and significant stock price decline (48.3% drop). Multiple material disclosures suggest prior non-disclosure of critical risks to investors.
Company faces federal securities fraud lawsuit for making false and misleading statements about drug candidate ERAS-0015. Disclosed patent infringement allegations and a patient death in clinical trials, resulting in a 54% stock price decline over two trading days from $21.49 to $9.90 per share.
The company is the subject of a securities class action lawsuit alleging material misrepresentations about its lead drug candidate, improper competitive comparisons, and undisclosed patent/trade secret risks. These allegations suggest significant corporate governance and disclosure failures that resulted in investor losses.
Class action alleges improper preclinical data comparisons and patent/trade secret violation risks were not disclosed to investors.
The company faces a class action lawsuit alleging false and misleading statements about its lead drug candidate ERAS-0015. A patent infringement claim from Revolution Medicines triggered a 48% stock price decline, indicating serious legal and commercial risks to the company's operations and credibility.
The company is accused of making false and misleading statements about its lead drug candidate, failing to disclose improper comparisons, patent/trade secret disputes, and lacking reasonable basis for claims. These allegations resulted in investor damages and a class action lawsuit.
The company faces a class action lawsuit alleging false and misleading statements about its lead drug candidate ERAS-0015. A patent infringement allegation from a competitor resulted in a severe 48% stock price drop, indicating significant legal and commercial risks to the company.
Company is accused of securities fraud involving false and misleading statements about its lead drug candidate, patent infringement disputes, undisclosed patient death in clinical data, and resulted in a 45% stock price decline.
Strong institutional backing from RTW Investments' $189M investment, 800% stock appreciation over the past year, encouraging early clinical data for lead candidate ERAS-0015 showing robust responses in KRAS-driven cancers, favorable safety profile, strategic partnerships with Tango Therapeutics and Merck, and adequate cash runway into late 2028 to advance development programs.
Articles that tag ERAS but are mainly about other companies.
Listed as subject to shareholder investigation alert for potential breaches of fiduciary duty, indicating similar governance concerns as Embecta.
Company is subject to a securities class action lawsuit with an August 10 deadline for lead plaintiff motions, suggesting alleged securities violations and investor losses.
Company is subject to a securities class action lawsuit filed by Rosen Law Firm with an August 10 deadline, indicating alleged misconduct that resulted in investor losses exceeding $100,000.
Company is subject to a securities class action lawsuit with an August 10, 2026 lead plaintiff deadline, suggesting alleged misconduct or misstatements affecting investors.
Company is subject to a securities class action lawsuit with an August 10, 2026 lead plaintiff deadline, indicating alleged securities violations, though specific details are not provided in the article excerpt.
Company is subject to securities class action lawsuit, though specific allegations are not detailed in the provided excerpt. The mere existence of litigation indicates investor concerns and potential legal/financial exposure.
Subject of a class action lawsuit filed by Rosen Law Firm, indicating alleged securities violations and investor losses, though specific details are not provided in the excerpt.
Company is named in a securities fraud class action lawsuit filed by Block & Leviton, indicating alleged investor deception and potential financial liability.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
